Mirati Therapeutics (MRTX) Earning Somewhat Favorable News Coverage, Study Shows
News articles about Mirati Therapeutics (NASDAQ:MRTX) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.3033478190391 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- -$0.62 EPS Expected for Mirati Therapeutics, Inc. (MRTX) This Quarter (americanbankingnews.com)
- Comparing SIGA Technologies (SIGA) and Mirati Therapeutics (MRTX) (americanbankingnews.com)
- Mirati Therapeutics, Inc. (MRTX) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Comparing Mirati Therapeutics (MRTX) and ContraFect (CFRX) (americanbankingnews.com)
Shares of Mirati Therapeutics (NASDAQ MRTX) traded down $0.40 during trading on Friday, hitting $18.70. The stock had a trading volume of 234,793 shares, compared to its average volume of 353,876. The firm has a market capitalization of $504.79, a P/E ratio of -6.01 and a beta of 1.61. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $19.70.
Several brokerages recently issued reports on MRTX. SunTrust Banks reiterated a “buy” rating and issued a $13.00 price target on shares of Mirati Therapeutics in a report on Monday, October 2nd. CIBC began coverage on Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $18.00 target price for the company. ValuEngine downgraded Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Finally, Cann began coverage on Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $13.71.
In other news, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the transaction, the senior vice president now owns 10,169 shares of the company’s stock, valued at $142,366. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Mirati Therapeutics (MRTX) Earning Somewhat Favorable News Coverage, Study Shows” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/07/mirati-therapeutics-mrtx-earning-somewhat-favorable-news-coverage-study-shows.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Stock Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related stocks with our FREE daily email newsletter.